Has anyone already received the dividend from $GILD (-1.15%) received? 27.6 was the original pay day
Gilead SciencesUS3755581036GILDGILD
$GILD (-1.15%) What do you think of the company? Somehow I have the feeling that there has been no downward stop for a year now.
$GILD (-1.15%) Gilead Science
This is now my tenth title in the healthcare sector
Market cap € 85 bn
P/E ratio approx. 13
Continuous increase in dividends
Double-digit profit growth with constant sales
Solidly filled pipeline (https://www.gilead.com/science-and-medicine/pipeline)
and ongoing acquisitions
Buy and hold, or add more if the share price weakens.
Financials
Market Cap
$104.44B5Y beta
0.19EPS (TTM)
$0.819Free Float
1.24BP/E ratio (TTM)
102.42Revenue (TTM)
$27.81BEBITDA (TTM)
$13.15BFree Cashflow (TTM)
$3.04BPricing
Analyst Ratings
The price target is $81.21 and the stock is covered by 29 analysts.
Buy
11
Hold
17
Sell
1
Information
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products includes AmBisome, Atripla, Biktarvy, Cayston, Complera, Descovy, Descovy for PrEP, Emtriva, Epclusa, Eviplera, Genvoya, Harvoni, Hepcludex, Hepsera, Jyseleca, Letairis, Odefsey, Sovaldi, Stribild, Sunlenca, Tecartus, Trodelvy, Truvada, Truvada for PrEP, Tybost, Veklury, Vemlidy, Viread, Vosevi, Yescarta and Zydelig. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, and Domvanalimab and zimberelimab, and seladelpar. Seladelpar shall be used for the treatment of primary biliary cholangitis (PBC), including pruritus. The Company operates in more than 35 countries.